Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF Profit Margin

As of the most recent data (June 2026), GERM shows a profit margin of 12.31%. That compares with 12.84% in the prior-year period — down 4.2% year over year. That is below the sector sector average of 13.09%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GERM's profit margin is now 12.31% (was 12.84%) — a 4.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF is outperforming or lagging.

The its sector sector average profit margin is about 13.09%. Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF is at 12.31%, which is lower that average. That is roughly 6.0% below the sector mean. Use the comparison chart on this page to see how GERM stacks up against individual peers as well.

That compares with 12.84% in the prior-year period — down 4.2% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 12.31%) with ownership activity and broader fundamentals.